SCHEMBL17084529

SCHEMBL17084529

C=C(C)C(=O)Nc1ccc(-c2ccc(OC(=O)C(=C)C)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.51
ELANE P08246 1/20 0.49
KMT2A Q03164 5/20 0.49
MEN1 O00255 3/20 0.49
BAZ1A Q9NRL2 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
HTT P42858 2/20 0.46
ATM Q13315 1/20 0.46
ALDH1A1 P00352 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PORCN Q9H237 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN11 Q06124 1/20 0.41
HSD17B10 Q99714 2/20 0.40
POLB P06746 2/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22082354 1.00 RXFP1 (0.51) RXFP1ELANEKMT2AMEN1BAZ1A
SCHEMBL12863515 0.95 RXFP1 (0.56) RXFP1ELANEKMT2AMEN1BAZ1A
SCHEMBL17084524 0.87 KMT2A (0.56) RXFP1ELANEKMT2AMEN1SMN1; SMN2
SCHEMBL17084527 0.87 KMT2A (0.56) RXFP1ELANEKMT2AMEN1SMN1; SMN2
SCHEMBL21350461 0.86 MMP1 (0.51) KMT2AMEN1SMN1; SMN2ALDH1A1MAPT
SCHEMBL22258851 0.85 MAPT (0.53) ELANEKMT2AMEN1SMN1; SMN2L3MBTL1
SCHEMBL17433304 0.85 ELANE (0.62) ELANEKMT2AMEN1HTTATM
SCHEMBL803168 0.85 ELANE (0.62) ELANEKMT2AMEN1HTTATM
SCHEMBL17084525 0.85 RXFP1 (0.67) RXFP1KMT2AMEN1BAZ1ASMN1; SMN2
SCHEMBL12872192 0.85 ELANE (0.62) ELANEKMT2AMEN1HTTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020230480-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT, AND COMPOUND DIC株式会社 2020-11-19 WO disclosed
US-9983441-B2 Liquid crystal display device MERCK PATENT GMBH (DE) 2018-05-29 US disclosed
US-20160168465-A1 MONOMER, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY DEVICE, AND PRODUCTION METHOD FOR LIQUID CRYSTAL DISPLAY DEVICE TOYO GOSEI CO., LTD. (JP) 2016-06-16 US disclosed
US-20150261044-A1 LIQUID CRYSTAL DISPLAY DEVICE SHARP KABUSHIKI KAISHA (JP) 2015-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168465-A1 MONOMER, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY DEVICE, AND PRODUCTION METHOD FOR LIQUID CRYSTAL DISPLAY DEVICE SP1, ZYX, NOD1 RXFP1 600/4885ELANE 3681/4885KMT2A 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.